Print
Email
Print Edition StoriesMonday, August 10, 2009
Millipore acquires drug/vaccine service firm BioAnaLab
By Mass High Tech staff
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Rodney Brown on NECN: Hacking into medical devices
Billerica-based life sciences firm Millipore Corp. has bought BioAnaLab, a biologic drug and vaccine analysis company based in the U.K.
BioAnaLab, which was formed in 2002 at the University of Oxford, tests and evaluates safety and effectiveness of drugs and vaccines through assay transfer and development, validation and sample analysis, immunogenicity, biological potency, and pharmacokinetics/toxicokinetics.
Millipore (NYSE: MIL) officials said in a press release that the acquisition will enable the company to expand its biopharmaceutical services to Europe. The financial terms of the deal were not disclosed. As part of the acquisition, BioAnaLab’s founder and CEO Geoff Hale will serve as Millipore’s director of biopharma services in Europe, working with Millipore chief scientist for biopharmaceutical services Ron Bowsher, based in the U.S.
Millipore, with more than 5,900 employees worldwide, reported a profit of $145.8 million on revenue of $1.6 billion for fiscal 2008.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
